Publications:108
Weiping Qin, MD, PhD
About Me
Dr. Weiping Qin’s research focuses on developing innovative therapeutic strategies to treat skeletal and neurological impairments associated with spinal cord injury (SCI). His work integrates approaches from molecular biology, neuroscience, and regenerative medicine to elucidate how injury-induced changes in signaling pathways and inflammation contribute to tissue degeneration.
Qin has used preclinical animal models to study severe skeletal health problems associated with SCI. The research focuses include developing novel pharmacological and non-pharmacological interventions [e.g., sclerostin antibodies (Ab), Siglec-15 Ab, androgens, vibration, and electrical stimulation]. One particular interest is to study osteocyte functions.
Qin has developed a novel cutting-edge nanomedicine approach for targeted delivery as effective and safe therapeutics for neuroprotection and functional recovery after acute SCI.
Qin’s recent work uncovers a novel mechanism underlying muscle-bone communication on maintain homeostasis of the local musculoskeletal environment through osteocytes by the generation and release exosomes that encapsulate miR-218.
Language
English
Position
PROFESSOR | Medicine, Pulmonary, Critical Care and Sleep Medicine
Publications
Selected Publications
- Administration of low intensity vibration and a RANKL inhibitor, alone or in combination, reduces bone loss after spinal cord injury-induced immobilization in rats. Yuanzhen Peng, Helen M. Bramlett, W. Dalton Dietrich, Alex Marcillo, Juliana Sanchez-Molano, Ofelia Furones-Alonso, Jay J. Cao, Jenney Huang, Andrew A. Li, Jian Q. Feng, William A. Bauman, Weiping Qin. Bone Reports
- Neuroprotective macromolecular methylprednisolone prodrug nanomedicine prevents glucocorticoid-induced muscle atrophy and osteoporosis in a rat model of spinal cord injury. Yiwen Qin, Wei Zhao, Zhenshan Jia, William A. Bauman, Yuanzhen Peng, X. Edward Guo, Zihao Chen, Zhiming He, Christopher P. Cardozo, Dong Wang, Weiping Qin. Nanomedicine: Nanotechnology, Biology, and Medicine
- Targeted-delivery of nanomedicine-enabled methylprednisolone to injured spinal cord promotes neuroprotection and functional recovery after acute spinal cord injury in rats. Wei Zhao, Zhenshan Jia, William A. Bauman, Yiwen Qin, Yuanzhen Peng, Zihao Chen, Christopher P. Cardozo, Dong Wang, Weiping Qin. Nanomedicine: Nanotechnology, Biology, and Medicine
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Dr. Qin has not yet completed reporting of Industry relationships.
Mount Sinai’s faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.